The hypoxia signaling pathway in the development of acute myeloid leukemia

This publication has 109 references indexed in Scilit:

• Survival impact of hypoxia-inducible factor-1 alpha (HIF-1α) in Nucleophosmin1 mutated acute myeloid leukemia
  Annals of Hematology, 2024
• Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial
  American Journal of Hematology, 2024
• Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells
  HemaSphere, 2024
• Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies
  American Journal of Hematology, 2023
• Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study group
  Hematological Oncology, 2020
• HIF‐1α forms regulatory loop with YAP to coordinate hypoxia‐induced adriamycin resistance in acute myeloid leukemia cells
  Cell Biology International, 2019
• Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia
  American Journal of Hematology, 2016
• Acute myeloid leukemia—Major progress over four decades and glimpses into the future
  American Journal of Hematology, 2015
• Regulation of Hypoxia-Inducible Factor-1a by Reactive Oxygen Species : New Developments in an Old Debate
  Journal of Cellular Biochemistry, 2015
• Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1α independent mechanisms
  Apoptosis, 2006